ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Mainz BioMed NV

Mainz BioMed NV (MYNZ)

1.03
0.0399
(4.03%)
Closed March 28 04:00PM
1.02
-0.01
(-0.97%)
After Hours: 05:02PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.02
Bid
1.02
Ask
1.05
Volume
35,959
1.0066 Day's Range 1.03
0.85 52 Week Range 6.70
Market Cap
Previous Close
0.9901
Open
1.03
Last Trade Time
Financial Volume
$ 36,808
VWAP
1.0236
Average Volume (3m)
90,093
Shares Outstanding
14,830,000
Dividend Yield
-
PE Ratio
-
Earnings Per Share (EPS)
-
Revenue
-
Net Profit
-

About Mainz BioMed NV

Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It's main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results. Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It's main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results.

Sector
Testing Laboratories
Industry
Testing Laboratories
Headquarters
Amsterdam, North Holland, Nld
Founded
1970
Mainz BioMed NV is listed in the Testing Laboratories sector of the NASDAQ with ticker MYNZ. The last closing price for Mainz BioMed NV was $0.99. Over the last year, Mainz BioMed NV shares have traded in a share price range of $ 0.85 to $ 6.70.

Mainz BioMed NV currently has 14,830,000 shares outstanding.

MYNZ Latest News

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

BERKELEY, Calif. and MAINZ, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for...

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for...

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

BERKELEY, Calif. and MAINZ, Germany, March 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for...

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive, to lead collaborationMainz Biomed’s Pivotal FDA PMA...

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

BERKELEY, Calif. and MAINZ, Germany, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for...

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

BERKELEY, Calif. and MAINZ, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for...

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for...

Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany

BERKELEY, Calif. and MAINZ, Germany, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for...

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium

BERKELEY, Calif. and MAINZ, Germany, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in...

Mainz Biomed Provides Year-End Corporate Review 2023

European Study ColoFuture and U.S. Study eAArly DETECT report sensitivity and specificity for the detection of Colorectal Cancer and Advanced Adenoma exceeding competitionReconAAsense designed to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.08-7.272727272731.11.10.952305801.02337611CS
40.077.368421052630.951.140.8546730690.98963266CS
12-0.13-11.30434782611.151.220.85900931.01566155CS
26-2.08-67.09677419353.13.39230.851608821.28885729CS
52-5.48-84.30769230776.56.70.851186962.27462967CS
156-13.33-92.891986062714.35300.851394789.88903046CS
260-13.33-92.891986062714.35300.851394789.88903046CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 22.08
(364.84%)
31.9M
NXLNexalin Technologies Inc
$ 1.50
(92.31%)
11.67M
CEROCERo Therapeutics Holdings Inc
$ 3.112
(90.92%)
24.08M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
KYCHKeyarch Acquisition Corporation
$ 12.30
(75.58%)
196.62k
BOLDBoundless Bio Inc
 14.25
(-76.24%)
767.63k
PMECPrimech Holdings Ltd
$ 1.2999
(-66.50%)
8.28M
TNXPTonix Pharmaceuticals Holding Corporation
$ 0.1816
(-44.45%)
21.92M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
NBSTWNewbury Street Acquisition Corporation
$ 0.042279
(-38.28%)
1.75k
NKLANikola Corporation
$ 1.035
(13.85%)
163.84M
GMDAGamida Cell Ltd
$ 0.036
(-39.19%)
89.18M
BDRXBiodexa Pharmaceuticals PLC
$ 1.6201
(88.60%)
88.37M
MARAMarathon Digital Holdings Inc
$ 22.56
(2.22%)
86.14M
AKANAkanda Corporation
$ 0.1166
(-29.29%)
80.34M

MYNZ Discussion

View Posts
Monksdream Monksdream 2 weeks ago
MYNZ under $2
👍️0
Monksdream Monksdream 1 month ago
MYNZ under $2
👍️0
Monksdream Monksdream 2 months ago
MYNZ new 52 week low
👍️0
D60510 D60510 3 months ago
Looking for strong upside for this stock in the March-June 2024 timeliness. Should be aver 3.00 imo
👍️0
gail gail 6 months ago
here comes the eod run up after the little dip there.
👍️0
gail gail 6 months ago
weeeeeee!
👍️0
gail gail 6 months ago
grabbed some this morning at 3.89.
👍️0
Triple nickle Triple nickle 11 months ago
Still stable
👍️0
BooDog BooDog 11 months ago
That cat bounced. Poped back over $4.
👍️0
BooDog BooDog 11 months ago
Watching for the dead cat bounce.
👍️0
Mrogers23 Mrogers23 12 months ago
$MYNZ Mainz Biomed Provides Full Year 2022 Financial Results

ColoAlert Revenue Increases 130% Year over Year

Year End Cash Balance of $17.1 Million

BERKELEY, Calif. and MAINZ, Germany, April 10, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the fiscal year ended December 31, 2022.
👍️0
Mrogers23 Mrogers23 1 year ago
This Could Send Mainz Biomed (MYNZ) Soaring Past Wainwright’s $25 Target https://smallcapexclusive.com/this-could-send-mainz-biomed-mynz-soaring-past-wainwrights-25-target/
👍️0
Mrogers23 Mrogers23 1 year ago
$MYNZ Analysts Model Over 74% Upside For Mainz Biomed Stock Ahead Of Key 1/H 2023 Updates https://www.benzinga.com/pressreleases/23/03/ab31469781/analysts-model-over-74-upside-for-mainz-biomed-stock-ahead-of-key-1h-2023-updates-mynz
👍️0
BEIJING BILL BEIJING BILL 1 year ago
But some... heering fda approval rumbles here.
👍️0
Mrogers23 Mrogers23 1 year ago
$MYNZ Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany

BERKELEY, Calif. and MAINZ, Germany, March 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr Staber & Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert, its flagship product that is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC). For more than 35 years, Labor Staber has been providing physicians and hospitals with medical laboratory services at nine locations across Germany.

Read for release: https://finance.yahoo.com/news/mainz-biomed-announces-partnership-labor-070100006.html
👍️0
Mrogers23 Mrogers23 1 year ago
$MYNZ Mainz Biomed Nears Multiple Data Set Releases Expected To Fuel 2023 Growth

Mainz Biomed's share price weakness presents an opportunity to trade ahead of potential near-term catalysts. Shares dropped on Monday, possibly in sympathy with the Silicon Valley Bankfiasco. However, while MYNZ does list a Berkeley, California connection on its byline, this company is primarily based in Germany. Thus, financial exposure, if any, is more of a distraction than an MYNZ-specific event. Moreover, its significance is outweighed by the planned data releases expected over the next 90 days.

Read full release:
👍️0
Mrogers23 Mrogers23 1 year ago
$MYNZ Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection

https://finance.yahoo.com/news/mainz-biomed-launches-number-educational-080100640.html
👍️0
Mrogers23 Mrogers23 1 year ago
Mainz Biomed has laid the groundwork in 2022 for what could be a transformative 2023. That means from a market cap perspective, its roughly $98 million level could be undervaluing much of the progress made last year. In fact, current valuations could be considered accurate if just historical evidence provided the model's input. But that's not the case. There's plenty of forward-looking considerations contributing to MYNZ's case of deserving a more appropriate and higher valuation. https://www.benzinga.com/pressreleases/23/02/ab31084658/mainz-biomeds-milestones-reached-in-2022-can-be-catalysts-in-1h-2023-heres-why-mynz
👍️0
cuggegrosse cuggegrosse 1 year ago
Very,very low float !!!!
👍️ 1
cuggegrosse cuggegrosse 1 year ago
If it ever comes !!!!!
👍️ 1
l2 hunter l2 hunter 1 year ago
MYNZ excellent NEWS OUT >>>>>>>>>> Looks like big time coming. Loaded some shares for 10 X potential for 2023/24 imho...

https://www.globenewswire.com/news-release/2022/12/06/2567955/0/en/Mainz-Biomed-Announces-IRB-Approval-and-Initiation-of-US-Pivotal-FDA-Clinical-Study.html


Ticker Buzz Cloud
24 Hours
12 Hours
6 Hours
3 Hours
1 Hour
AABB
AGYP
AITX
AMC
ANY
APCX
APSI
ARIS
AVXL
BIEL
BIG
BLUE
BOMO
BRLL
CAN
CGRA
CLNV
CNNA
COMS
COSM
CPHI
DBGI
DBMM
DRGV
ENZC
ERBB
FOR
GDVM
GOLD
GRPS
GVSI
ICNM
IGEX
IN
INKW
KBLB
KRTL
LLLI
MASN
MJLB
MRNA
MRNJ
MULN
NBLD
NWBO
PLAN
PVSP
REAL
SBEV
SNPW
SNTX
TMNA
TOPS
TPRFF
TSLA
UPIN
WNFT
WSRC
👍️0
esi23 esi23 1 year ago
FDA approval in USA will blow this up to 30-40. Market cap 140M

Outstanding 14 M
25% insider owned.

Long term winner
👍️0
BlazingStocks BlazingStocks 1 year ago
“The Company is financially well positioned to maintain momentum as ColoAlert continues to gain impressive commercial traction across Europe and select international territories, and as we ramp up to launch its U.S. pivotal clinical trial by the end of the year.”
- Guido Baechler, Chief Executive Officer of Mainz Biomed, $MYNZ
👍️0
BlazingStocks BlazingStocks 1 year ago
$MYNZ trading at the high of the day.

ColoAlert - The Company’s Flagship Product (ColoAlert) Could Become An Inexpensive Alternative In A $3.7 Billion Market? $MYNZ
https://investorbrandmedia.com/mynz-stock-alert/
👍️0
BlazingStocks BlazingStocks 1 year ago
Yes, $MYNZ had an amazing day yesterday... a continuation would be awesome.
👍️0
pumpnass pumpnass 1 year ago
Yesterday was a great day, let’s see if we can hold that trend today!!
👍️0
BlazingStocks BlazingStocks 1 year ago
$MYNZ - Mainz Biomed Strengthens Board of Directors...
*Dr. Dreismann, Former Roche Molecular Diagnostics CEO
*Over 35 years of experience in the life sciences and health care industries
*Mr. Tibbitts, a Highly-accomplished Life-Sciences Executive
*Certified Public Accountant with over 30 years of professional experience as a senior financial executive
*Together provide Extensive Experience in Diagnostics and Financial Strategy
https://finance.yahoo.com/news/mainz-biomed-strengthens-board-directors-110000523.html
👍️0
BlazingStocks BlazingStocks 1 year ago
Don't forget about this...$MYNZ - Another Value-Creating Asset, PancAlert...
*Advancing a second portfolio asset
*An early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR)
*Multiplex detection of molecular-genetic biomarkers in stool samples.
*Accurate real-time results
*Can be a first and best-in-class screening for pancreatic cancer
https://www.marketwatch.com/press-release/mainz-biomed-targets-multi-billion-dollar-sales-opportunities-with-best-in-class-cancer-screening-diagnostics-mynz-2022-09-26
👍️0
BlazingStocks BlazingStocks 1 year ago
$MYNZ coming up on 2x its 10-day average volume as we head into Power Hour... let's rock!
👍️0
budfoxfun budfoxfun 1 year ago
Bids increasing, heating up here!

$MYNZ
👍️0
budfoxfun budfoxfun 1 year ago
$MYNZ $25.8 million (gross) in new capital, having less than $1 million in long-term debt, and generating revenues from an early cancer detection diagnostics portfolio.
👍️0
BlazingStocks BlazingStocks 1 year ago
Should see $8 in power Hour again... $MYNZ
👍️0
BlazingStocks BlazingStocks 1 year ago
$MYNZ breakout! $8.01 hit and it's consolidating around $7.50... Power Hour should be interesting.
👍️0
budfoxfun budfoxfun 1 year ago
7.65 not much on the ask now, $8's coming!

$MYNZ
👍️0
budfoxfun budfoxfun 1 year ago
$MYNZ 7.65 up now, something brewing here!
👍️0
BlazingStocks BlazingStocks 1 year ago
WOWZA, really nice volume as $MYNZ now trading nearly 60% over its 10-day average volume with about 3 hours still left in the day... UP almost 2%.
👍️0
pumpnass pumpnass 1 year ago
Definitely picking up now
👍️0
BlazingStocks BlazingStocks 1 year ago
$MYNZ now trading nearly 10% over its 10-day average volume in lunchtime... Still holding steady.
👍️0
budfoxfun budfoxfun 1 year ago
$MYNZ hot sector here:
👍️0
BlazingStocks BlazingStocks 1 year ago
Nice premarket volume and it's continuing into the open...might break its 10-day average volume within the first hour.
👍️0
BlazingStocks BlazingStocks 1 year ago
Wow, great News this morning! $MYNZ trading nearly 70% of its 10-day average volume within the first 30 minutes...and holding steady near yesterday's close.
👍️0
budfoxfun budfoxfun 1 year ago
Looks ready for new highs on the week, ask is super thin now!

$MYNZ
👍️0
pumpnass pumpnass 1 year ago
Nice pre market volume
👍️0
budfoxfun budfoxfun 1 year ago
“As we continue to build strength throughout our organization, we are honored to nominate Heiner and Gregory to our Board of Directors, two notable leaders in key areas of the diagnostics field,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “The rich experience they would bring to our board, in both strategic development and financial stewardship, will be of significant value as we prepare for our imminent and pivotal US clinical trial for ColoAlert and continue to advance the development and commercialization of our portfolio of next-generation early-cancer detection products.”

$MYNZ
👍️0
budfoxfun budfoxfun 1 year ago
$MYNZ Mid-year cash balance of $26 Million
👍️0
pumpnass pumpnass 1 year ago
That’s what I like to see!!
👍️0
budfoxfun budfoxfun 1 year ago
$MYNZ News Out! Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts https://finance.yahoo.com/news/mainz-biomed-strengthens-board-directors-110000523.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
👍️0
BlazingStocks BlazingStocks 2 years ago
Let's see if we can get one more push to close green. $MYNZ

Biotech Stocks could be recession proof as bond market plunges (MYNZ, RVNC, AXSM, ABBV)
https://www.marketwatch.com/press-release/biotech-stocks-could-be-recession-proof-as-bond-market-plunges-mynz-rvnc-axsm-abbv-2022-09-26?mod=mw_quote_news_seemore
👍️0
BlazingStocks BlazingStocks 2 years ago
Agreed... The saying goes "Buy when there's blood in the streets." $MYNZ is working towards FDA approval.

Received supportive feedback from the U.S. Food and Drug Administration (FDA) on ColoAlert’s pre-submission package for its U.S. pivotal clinical trial set to commence in Q4 2022.
👍️0
BlazingStocks BlazingStocks 2 years ago
$MYNZ - Expanded Strategic Advisory Board of global leaders in molecular diagnostic development and commercialization.
https://finance.yahoo.com/news/mainz-biomed-reports-first-half-070100420.html


👍️0

Your Recent History

Delayed Upgrade Clock